300 filings
8-K
OGEN
Oragenics Inc
23 May 24
Shareholder Nominations Pursuant to Exchange Act Rule 14a-11
9:27am
8-K
OGEN
Oragenics Inc
22 May 24
Oragenics Appoints William “Frank” Peacock MD as Chief Clinical Officer
8:00am
8-K
OGEN
Oragenics Inc
17 May 24
Other Events
8:00am
8-K
OGEN
Oragenics Inc
16 May 24
Other Events
8:00am
8-K
OGEN
Oragenics Inc
7 May 24
Oragenics Partners with Avance Clinical for Phase II Concussion Trial in Australia
8:14am
8-K
3xo2c02od24vs4anj1ub
19 Apr 24
Oragenics, Inc. Announces Notification of Noncompliance with Additional NYSE American Continued Listing Standards
5:48pm
8-K
pi3h z4m8
15 Apr 24
Shareholder Nominations Pursuant to Exchange Act Rule 14a-11
8:01pm
8-K
dqo8cyyfezdjw3
18 Mar 24
Oragenics Appoints James Kelly MD, Chief Medical Officer to Lead Phase II Clinical Trials for Treating Concussion
7:38am
8-K
ztm1ezj4vxxjwpyj9cc
1 Mar 24
Oragenics Announces Closing of Public Offering
4:05pm
8-K
3mmkjnk 0cy
28 Feb 24
Oragenics Announces Pricing of Public Offering
9:03am
8-K
le0t6f1
27 Feb 24
Oragenics Announces Proposed Public Offering
5:48pm
8-K
45dvlbyr
12 Feb 24
Oragenics, Inc. Announces Leadership Transition
4:45pm
8-K
xmrt2lky6yrkbo
7 Feb 24
Oragenics, Inc. Announces Expiration of Its Investment Banking Engagement Agreement
8:00am
8-K
ou3mtx9t129nb00
5 Feb 24
Other Events
8:00am
8-K
yxp7qbow
23 Jan 24
Oragenics Announces Termination of At-The-Market Offering Program
5:18pm
8-K
lr6kv24zgc0pq8sjy3p6
16 Jan 24
Other Events
9:10am
8-K
lhdq6g5
2 Jan 24
Oragenics Completes Acquisition of Odyssey Health’s Neurological Assets
9:22am
8-K
h3nktd7r2y81w0s1zx
29 Dec 23
Completion of Acquisition or Disposition of Assets
7:30am
8-K
9xpz9euh2unbwcxm 35
15 Dec 23
Material Modifications to Rights of Security Holders
3:45pm
8-K
0k6modib 9q
8 Dec 23
Amendments to Articles of Incorporation or Bylaws
4:00pm